Life sciences technology business Abselion has introduced the Protein G Total Antibody Quantification Kit, specifically designed for compatibility with the company’s Amperia benchtop platform.
This kit complements the existing Protein A-based format, enabling the quantification of a wider range of antibody isotypes and species using the same protocol-guided workflow and sensitive electrochemical detection.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The Amperia platform claims to quickly automate the quantification of multiple biomolecules, operating without the need for optical or fluidic components.
Abselion’s newly released kit comes as a complete package, comprising Protein G-coated sensor strips, detection reagents, buffers, and plates, ready for immediate application in both research and process development settings.
In conjunction with Amperia’s software and guided instructions, the kit enables researchers to obtain antibody titre data, circumventing the complexities and specialised training often associated with such measurements.
The quantification process employs sensor strips pre-coated with Protein G for the direct antibody capture from samples.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataA labelled detection molecule subsequently attaches to any unoccupied fragment crystallisable (Fc)-binding sites on the sensor.
This interaction occurs at the sensor tip, triggering an electrical signal that Amperia reads in real time. The signal generated is inversely proportional to the concentration of the antibody.
According to the company, traditional quantitative methods like bio-layer interferometry and surface plasmon resonance are typically confined to central analytical labs because of their high cost and operational complexity, often causing delays and necessitating sample storage.
Abselion’s Amperia system presents an automated alternative for antibody titre assessment.
Abselion founder and CEO Dr Ruizhi Wang said: “Antibody-based research and development often involves a wide variety of formats, subclasses, and species. Having the flexibility to choose the most appropriate assay without adjusting workflows can simplify decision-making and improve efficiency.
“This launch reflects Abselion’s commitment to evolving its platform in response to real-world research needs. Expanding our antibody quantification offering with Protein G allows us to better support scientists working with a broader range of antibody formats, and reflects our ongoing focus on making practical, application-driven tools more accessible.”
